Press Releases Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Market Closed - Nasdaq Other stock markets 21:00:00 08/05/2024 BST			5-day change	1st Jan Change
13.61 ^USD	-20.92%		-17.47%	+99.56%

05-07	Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q1 Revenue $19.9M, vs. Street Est of $22.2M	MT
05-07	Y-mAbs Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments	05-07	AQ
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024	04-26	AQ
Y-mAbs to Present at 2024 ASCO Annual Meeting	04-25	AQ
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer	03-14	AQ
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors	03-04	AQ
Y mAbs Therapeutics : mAbs Appoints Oncolog Executive Mar Tagliaferri, M.D. to its Board of Directors - Form 8-K	03-04	PU
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments	02-29	AQ
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)	02-21	AQ
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024	02-16	AQ
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference	01-02	AQ
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)	12-22	AQ
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index	12-13	AQ
Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments	11-13	AQ
Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023	31/10/23	AQ
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director	18/10/23	AQ
Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA	17/10/23	AQ
Y-mAbs Announces Publication in Cancers	16/10/23	AQ
Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Y-mAbs Therapeutics Inc. (NASDAQ: YMAB)	21/09/23	PR
Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology	21/09/23	AQ
Y-mAbs to Participate at Upcoming Investor Conferences in September	06/09/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Press Releases

Filters